The Addario Lung Cancer Medical Institute (ALCMI) and Scancell Holdings have partnered to evaluate Scancell's cancer vaccine SCIB2 in a Phase I/II trial to treat non-small-cell lung cancer (NSCLC).

SCIB2 is a vaccine designed to stimulate immune responses to specific lung cancer antigens and help the body to target and fight NSCLC.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The vaccine has been developed as part of Scancell's ImmunoBody cancer vaccine platform, a new immunotherapy treatment under development that activates the immune system to treat and prevent cancer.

It stimulates both the helper cell system and the cytotoxic T-lymphocyte part of the immune system.

"The results showed that SCIB1 monotherapy effects tumour load, generates a melanoma-specific immune response and showed a survival trend without serious side effects."

Scancell chief executive officer Richard Goodfellow said: "We have generated preclinical data that suggests that SCIB2 could be the ideal complement to existing and emerging checkpoint inhibitor therapies to treat NSCLC and so provide an effective new potential treatment option for patients with this devastating disease."

The firm has claimed to have successfully completed a Phase I/II clinical trial of SCIB1 in patients with melanoma.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The results showed that SCIB1 monotherapy effects tumour load, generates a melanoma-specific immune response and showed a survival trend without serious side effects.

Pre-clinical data on SCIB1 or SCIB2 combination therapy and checkpoint inhibition have indicated increased tumour destruction and longer survival times in comparison to monotherapy.

ALCMI is expected to begin next year and intends to aid Scancell in the design and development of a Phase I/II clinical trial of SCIB2 in patients with NSCLC.